<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LITHIUM CARBONATE- lithium carbonate capsule </strong><br>McKesson Packaging Services a business unit of McKesson Corporation<br></p></div>
<h1>
<span class="Bold">LITHIUM CARBONATE</span><br><span class="Bold">CAPSULES, USP</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_773246b0-9211-40cb-8f20-7585f0828b06"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx Only</span></p>
</div>
<div class="Warning">
<a name="id_1f8e1016-a13c-464c-a072-83296f98dea3"></a><a name="section-2"></a><p></p>
<h1>WARNING</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Lithium toxicity</span> is closely related to serum lithium levels, and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy. (see <span class="Bold"><a href="#i4i_dosage_admin_id_957ba0dd-6b9e-49d3-85bd-b34191fb3a2f">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_36aca60a-5eca-4296-b002-6bede24b53e9"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each capsule for oral administration contains 150 mg, 300 mg or 600 mg of lithium carbonate. In addition, each capsule contains the following inactive ingredient:</p>
<p>150 mg: Talc.</p>
<p>300 mg: Talc.</p>
<p>600 mg: Colloidal Silicon Dioxide, Stearic Acid and Talc.</p>
<p>Capsule shell for the 150 mg potency contains: Gelatin and Titanium Dioxide.</p>
<p>Capsule shell for the 300 mg potency contains: D&amp;C Yellow #10, FD&amp;C Green #3, FD&amp;C Red #40, FD&amp;C Yellow #6, Gelatin and Titanium Dioxide.</p>
<p>Capsule shell for the 600 mg potency contains: Titanium Dioxide, Gelatin and FD&amp;C Red #40.</p>
<p>The printing ink contains: D&amp;C Yellow #10, FD&amp;C Blue #1, FD&amp;C Blue #2, FD&amp;C Red #40, n-Butyl Alcohol, Pharmaceutical Glaze, Propylene Glycol, SDA-3A Alcohol, and Synthetic Black Iron Oxide.</p>
<p>Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94 and an emission line at 671 nm on the flame photometer.</p>
<p>Lithium Carbonate is a white, light, alkaline powder with molecular formula Li<span class="Sub">2</span>CO<span class="Sub">3</span> and molecular weight 73.89.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_11efb129-53f7-4c1d-b87e-1d54c414f231"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Preclinical studies have shown that lithium alters sodium transport in nerve and muscle cells and effects a shift toward intraneuronal metabolism of catecholamines, but the specific biochemical mechanism of lithium action in <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> is unknown.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_0a5db896-f15a-4538-be28-3ae7147cc06e"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Lithium is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episodes</span> of Bipolar Disorder. Bipolar Disorder, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> (DSM-III) is equivalent to <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Manic Depressive illness</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span>, in the older DSM-II terminology.</p>
<p>Lithium is also indicated as a maintenance treatment for individuals with a diagnosis of Bipolar Disorder.</p>
<p>Maintenance therapy reduces the frequency of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episodes</span> and diminishes the intensity of those episodes which may occur.</p>
<p>Typical symptoms of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> include pressure of speech, motor <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, and possibly <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>. When given to a patient experiencing a <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span>, lithium may produce a normalization of symptomatology within 1 to 3 weeks.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_f0ea6747-03bd-4296-8207-2c0c7af762f4"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Lithium should generally not be given to patients with significant renal or cardiovascular disease, severe debilitation or <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, or <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">sodium depletion</span>, and to patients receiving diuretics, since the risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> is very high in such patients. If the psychiatric indication is life-threatening, and if such a patient fails to respond to other measures, lithium treatment may be undertaken with extreme caution, including daily serum lithium determinations and adjustment to the usually low doses ordinarily tolerated by these individuals. In such instances, hospitalization is a necessity.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_dd0f3140-c167-4a8c-a692-6832eaf9dd97"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Lithium may cause fetal harm when administered to a pregnant woman. There have been reports of lithium having adverse effects on nidations in rats, embryo viability in mice, and metabolism in-vitro of rat testis and human spermatozoa have been attributed to lithium, as have <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in submammalian species and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span> in mice. Studies in rats, rabbits and monkeys have shown no evidence of lithium-induced teratology. Data from lithium birth registries suggest an increase in cardiac and other anomalies, especially Ebstein's anomaly. If the patient becomes pregnant while taking lithium, she should be apprised of the potential risk to the fetus. If possible, lithium should be withdrawn for at least the first trimester unless it is determined that this would seriously endanger the mother.</p>
<p>Chronic lithium therapy may be associated with diminution of renal concentrating ability, occasionally presenting as <span class="product-label-link" type="condition" conceptid="438476" conceptname="Nephrogenic diabetes insipidus">nephrogenic diabetes insipidus</span>, with <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> and <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>. Such patients should be carefully managed to avoid <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> with resulting lithium retention and toxicity. This condition is usually reversible when lithium is discontinued.</p>
<p>Morphologic changes with glomerular and interstitial <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> and nephron-<span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> have been reported in patients on chronic lithium therapy. Morphologic changes have also been seen in bipolar patients never exposed to lithium. The relationship between renal functional and morphologic changes and their association with lithium therapy has not been established.</p>
<p>When kidney function is assessed, for baseline data prior to starting lithium therapy or thereafter, routine urinalysis and other tests may be used to evaluate tubular function (e.g., urine specific gravity or <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> following a period of water deprivation, or 24-hour urine volume) and glomerular function (e.g., serum creatinine or creatinine clearance). During lithium therapy, progressive or sudden changes in renal function, even within the normal range, indicate the need for reevaluation of treatment.</p>
<p><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Lithium toxicity</span> is closely related to serum lithium levels, and can occur at doses close to therapeutic levels (see <span class="Bold"><a href="#i4i_dosage_admin_id_957ba0dd-6b9e-49d3-85bd-b34191fb3a2f">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_ec8dbfa6-9e83-4900-96ac-23ae3048758d"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_65972b95-b1dd-4fa6-b62a-065fa2b24368"></a><a name="section-7.1"></a><p></p>
<h2><span class="Italics">General:</span></h2>
<p class="First">The ability to tolerate lithium is greater during the acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> phase and decreases when <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptoms subside (see <span class="Bold"><a href="#i4i_dosage_admin_id_957ba0dd-6b9e-49d3-85bd-b34191fb3a2f">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>The distribution space of lithium approximates that of total body water. Lithium is primarily excreted in urine with insignificant excretion in feces. Renal excretion of lithium is proportional to its plasma concentration. The half-life of elimination of lithium is approximately 24 hours. Lithium decreases sodium reabsorption by the renal tubules which could lead to <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">sodium depletion</span>. Therefore, it is essential for the patient to maintain a normal diet, including salt, and an adequate fluid intake (2500-3000 mL) at least during the initial stabilization period. Decreased tolerance to lithium has been reported to ensue from protracted <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and, if such occur, supplemental fluid and salt should be administered.</p>
<p>In addition to <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, concomitant <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with elevated temperatures may also necessitate a temporary reduction or cessation of medication.</p>
<p>Previously existing underlying <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">thyroid disorders</span> do not necessarily constitute a contraindication to lithium treatment; where <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> exists, careful monitoring of thyroid function during lithium stabilization and maintenance allows for correction of changing thyroid parameters, if any. Where <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> occurs during lithium stabilization and maintenance, supplemental thyroid treatment may be used.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_dd2fbc4a-96e0-48e7-82fe-9e87dbf4b204"></a><a name="section-7.2"></a><p></p>
<h2><span class="Italics">Information for the Patients:</span></h2>
<p class="First">Outpatients and their families should be warned that the patient must discontinue lithium therapy and contact his physician if such clinical signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> as <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, mild <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, or <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span> occur.</p>
<p>Lithium may impair mental and/or physical abilities. Caution patients about activities requiring alertness (e.g., operating vehicles or machinery).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_07255bbb-c0f8-44e7-9096-810ea9f51aae"></a><a name="section-7.3"></a><p></p>
<h2><span class="Italics">Drug Interactions:</span></h2>
<p class="First">Combined use of haloperidol and lithium. An encephalopathic syndrome (characterized by <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremulousness</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, elevated serum enzymes, BUN and FBS) followed by irreversible <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span> has occurred in a few patients treated with lithium plus haloperidol. A causal relationship between these events and the concomitant administration of lithium and haloperidol has not been established; however, patients receiving such combined therapy should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if such signs appear.</p>
<p>The possibility of similar adverse interactions with other antipsychotic medication exists.</p>
<p>Lithium may prolong the effects of neuromuscular blocking agents. Therefore, neuromuscular blocking agents should be given with caution to patients receiving lithium.</p>
<p>Caution should be used when lithium and diuretics or angiotensin converting enzyme (ACE) inhibitors are used concomitantly because sodium loss may reduce the renal clearance of lithium and increase serum lithium levels with risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. When such combinations are used, the lithium dosage may need to be decreased, and more frequent monitoring of lithium plasma levels is recommended.</p>
<p>Non-Steroidal Anti-Inflammatory Drugs (NSAIDS): Lithium levels should be closely monitored when patients initiate or discontinue NSAID use. In some cases, <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> has resulted from interactions between an NSAID and lithium. Indomethacin and piroxicam have been reported to increase significantly steady-state plasma lithium concentrations. There is also evidence that other nonsteriodal anti-inflammatory agents, including the selective cyclooxygenase-2 (COX-2) inhibitors, have the same effect. In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with celecoxib 200 mg BID as compared to subjects receiving lithium alone.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_e4f61f51-dc78-4982-9771-a53ffd86221a"></a><a name="section-7.4"></a><p></p>
<h2><span class="Italics">Pregnancy, Teratogenic Effects: Pregnancy Category D.</span></h2>
<p class="First">See <span class="Bold"><a href="#i4i_warnings_id_dd0f3140-c167-4a8c-a692-6832eaf9dd97">WARNINGS</a></span> section.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_0e4d128b-82f0-4c61-ace8-69274478302a"></a><a name="section-7.5"></a><p></p>
<h2><span class="Italics">Nursing Mothers:</span></h2>
<p class="First">Lithium is excreted in human milk. Nursing should not be undertaken during lithium therapy except in rare and unusual circumstances where, in the view of the physician, the potential benefits to the mother outweigh possible hazards to the child.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_0e750835-628f-4b43-87b6-61e30927bacc"></a><a name="section-7.6"></a><p></p>
<h2><span class="Italics">Pediatric Use:</span></h2>
<p class="First">Since information regarding the safety and effectiveness of lithium in children under 12 years of age is not available, its use in such patients is not recommended at this time. There has been a report of a transient syndrome of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span> and <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span> occurring in a 15 kg child who ingested 300 mg of lithium carbonate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_4d4fe6eb-c327-47dd-b146-0e54f1251485"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_537125dd-fe6a-40e0-8716-1fad3bdda117"></a><a name="section-8.1"></a><p></p>
<h2><span class="Italics"><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Lithium Toxicity</span>:</span></h2>
<p class="First">The likelihood of toxicity increases with increasing serum lithium levels. Serum lithium levels greater than 1.5 mEq/L carry a greater risk than lower levels. However, patients sensitive to lithium may exhibit toxic signs at serum levels below 1.5 mEq/L.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span> and <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">lack of coordination</span> may be early signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>, and can occur at lithium levels below 2 mEq/L. At higher levels, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">giddiness</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, and a large output of dilute urine may be seen. Serum lithium levels above 3 mEq/L may produce a complex clinical picture involving multiple organs and organ systems. Serum lithium levels should not be permitted to exceed 2 mEq/L during the acute treatment phase.</p>
<p>Fine hand <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> and mild <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span> may occur during initial therapy for the acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> phase, and may persist throughout treatment. Transient and mild <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">general discomfort</span> may also appear during the first few days of lithium administration.</p>
<p>These side effects are an inconvenience rather than a disabling condition, and usually subside with continued treatment or a temporary reduction or cessation of dosage. If persistent, a cessation of dosage is indicated.</p>
<p>The following adverse reactions have been reported and do not appear to be directly related to serum lithium levels.</p>
<p><span class="Italics">Neuromuscular:</span> <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span>, muscle hyperirritability (<span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">fasciculations</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="4270553" conceptname="Clonus">clonic movements</span> of whole limbs), <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, choreo-athetotic movements, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> deep tendon reflexes.</p>
<p><span class="Italics">Central Nervous System:</span> <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">Blackout spells</span>, epileptiform <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">incontinence of urine</span> or feces, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4160898" conceptname="Motor retardation">psychomotor retardation</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span>, downbeat <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>.</p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, peripheral <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, sinus node dysfunction with severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (which may result in <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>).</p>
<p><span class="Italics">Neurological:</span> Cases of <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span> (<span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> and <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>) have been reported with lithium use. If undetected, this condition may result in enlargement of the blind spot, constriction of visual fields and eventual <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> due to <span class="product-label-link" type="condition" conceptid="372914" conceptname="Optic atrophy">optic atrophy</span>. Lithium should be discontinued, if clinically possible, if this syndrome occurs.</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p><span class="Italics">Genitourinary:</span> <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">Albuminuria</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>.</p>
<p><span class="Italics">Dermatologic:</span> Drying and thinning of hair, anesthesia of skin, chronic <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, xerosis cutis, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> and <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">exacerbation of psoriasis</span>.</p>
<p><span class="Italics">Autonomic Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</p>
<p><span class="Italics">Thyroid Abnormalities:</span> <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">Euthyroid goiter</span> and/or <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> (including <span class="product-label-link" type="condition" conceptid="4182596" conceptname="Myxedema">myxedema</span>) accompanied by lower T<span class="Sub">3</span> and T<span class="Sub">4</span>. Iodine uptake may be elevated. (See <span class="Bold"><a href="#i4i_precautions_id_ec8dbfa6-9e83-4900-96ac-23ae3048758d">PRECAUTIONS</a></span>.) Paradoxically, rare cases of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> have been reported.</p>
<p><span class="Italics">EEG Changes:</span> Diffuse slowing, widening of the frequency spectrum, potentiation and disorganization of background rhythm.</p>
<p><span class="Italics">EKG Changes:</span> Reversible flattening, isoelectricity or inversion of T-waves.</p>
<p><span class="Italics">Miscellaneous:</span> <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, transient scotomata, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, tendency to sleep.</p>
<p><span class="Italics">Miscellaneous reactions unrelated to dosage are:</span> Transient electroencephalographic and electrocardiographic changes, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, diffuse non-toxic <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> with or without <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, transient <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, generalized pruritis with or without <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, cutaneous <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, worsening of <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">organic brain syndromes</span>, excessive <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, edematous <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of ankles or wrists, and <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span> or <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, sometimes resembling <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span>, and metallic taste.</p>
<p>A single report has been received of the development of painful discoloration of fingers and toes and <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">coldness</span> of the extremities within one day of the starting of treatment of lithium. The mechanism through which these symptoms (resembling Raynaud's Syndrome) developed is not known. Recovery followed discontinuance.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_031b1c37-06d3-4594-8a51-d62aded49df4"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The toxic levels for lithium are close to the therapeutic levels. It is therefore important that patients and their families be cautioned to watch for early toxic symptoms and to discontinue the drug and inform the physician should they occur. Toxic symptoms are listed in detail under <span class="Bold"><a href="#i4i_adverse_effects_id_4d4fe6eb-c327-47dd-b146-0e54f1251485">ADVERSE REACTIONS</a></span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_68e1ab85-3071-4d72-a7ad-d5c0760ef567"></a><a name="section-9.1"></a><p></p>
<h2>Treatment</h2>
<p class="First">No specific antidote for <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium poisoning</span> is known. Early symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> can usually be treated by reduction or cessation of dosage of the drug and resumption of the treatment at a lower dose after 24 to 48 hours. In severe cases of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium poisoning</span>, the first and foremost goal of treatment consists of elimination of this ion from the patient.</p>
<p>Treatment is essentially the same as that used in barbiturate <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>: 1) gastric lavage, 2) correction of fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> and 3) regulation of kidney functioning. Urea, mannitol and aminophylline all produce significant increases in lithium excretion. Hemodialysis is an effective and rapid means of removing the ion from the severely toxic patient. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> prophylaxis, regular chest X-rays, and preservation of adequate respiration are essential.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_957ba0dd-6b9e-49d3-85bd-b34191fb3a2f"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Acute Mania</span> -</span> Optimal patient response to Lithium Carbonate usually can be established and maintained with 600 mg t.i.d. Such doses will normally produce an effective serum lithium level ranging between 1 and 1.5 mEq/L. Dosage must be individualized according to serum levels and clinical response. Regular monitoring of the patient's clinical state and serum lithium levels is necessary. Serum levels should be determined twice per week during the acute phase, and until the serum level and clinical condition of the patient have been stabilized.</p>
<p><span class="Italics">Long-Term Control -</span> The desirable serum lithium levels are 0.6 to 1.2 mEq/L. Dosage will vary from one individual to another, but usually 300 mg of Lithium Carbonate t.i.d. or q.i.d. will maintain this level. Serum lithium levels in uncomplicated cases receiving maintenance therapy during remission should be monitored at least every two months.</p>
<p>Patients abnormally sensitive to lithium may exhibit toxic signs at serum levels of 1 to 1.5 mEq/L. Elderly patients often respond to reduced dosage, and may exhibit signs of toxicity at serum levels ordinarily tolerated by other patients.</p>
<p><span class="Italics">N.B.:</span> Blood samples for serum lithium determination should be drawn immediately prior to the next dose when lithium concentrations are relatively stable (i.e., 8-12 hours after the previous dose). Total reliance must not be placed on serum levels alone. Accurate patient evaluation requires both clinical and laboratory analysis.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_ad94755f-b166-4f76-946d-8391b4a9284e"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Lithium Carbonate Capsules USP, 300 mg are supplied as No. 1 Grey/Yellow Opaque Hard Gelatin Capsules Printed "West-ward 3189" in Black Ink and are available in:</p>
<p>Boxes of UD100 NDC 63739-265-10         </p>
<p>Store at 20-25°C (68-77°F) [See USP Controlled Room Temperature]. Protect from light and moisture.</p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
<p>Manufactured By:<br><span class="Bold">West-ward Pharmaceutical Corp.</span></p>
<p>401 Industrial Way West<br> Eatontown, NJ 07724</p>
<p>Distributed by:</p>
<p><span class="Bold">McKesson Packaging Services</span></p>
<p>a business unit of McKesson Corporation</p>
<p>7101 Weddington Rd., Concord, NC 28027</p>
<p>IS-4001892-R4</p>
<p>July 2011</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_1b727b11-49bc-4bd2-828a-8620c87b0e24"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id520"></a><img alt="Lithium Carbonate Capsules 300mg label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bc99fa8c-1d8b-4363-b616-548c62594076&amp;name=f051f7f1-5b1d-4256-af2b-266cef308233-01.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LITHIUM CARBONATE 		
					</strong><br><span class="contentTableReg">lithium carbonate capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63739-265(NDC:0143-3189)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LITHIUM CARBONATE</strong> (LITHIUM CATION) </td>
<td class="formItem">LITHIUM CARBONATE</td>
<td class="formItem">300 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C GREEN NO. 3</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GRAY, YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">20mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">WW;3189</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63739-265-10</td>
<td class="formItem">10  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076243</td>
<td class="formItem">07/19/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>McKesson Packaging Services a business unit of McKesson Corporation
							(140529962)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">McKesson Packaging Services a business unit of McKesson Corporation</td>
<td class="formItem"></td>
<td class="formItem">140529962</td>
<td class="formItem">REPACK(63739-265)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f051f7f1-5b1d-4256-af2b-266cef308233</div>
<div>Set id: bc99fa8c-1d8b-4363-b616-548c62594076</div>
<div>Version: 2</div>
<div>Effective Time: 20140204</div>
</div>
</div> <div class="DistributorName">McKesson Packaging Services a business unit of McKesson Corporation</div></p>
</body></html>
